ArticleLaryngoscope investigative otolaryngology2026
Blood Eosinophil Count and Lund-Mackay Ethmoid Score as Predictors of Recurrence After Endoscopic Sinus Surgery in CRSwNP.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the incremental prognostic value of blood eosinophil count (BEC) and Lund-Mackay (LM) ethmoid score beyond age and asthma for recurrence after endoscopic sinus surgery (ESS) in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). Methods: This retrospective cohort included adults with CRSwNP undergoing ESS from January 2022 to November 2024. The outcome was endoscopically confirmed recurrence. Cox models included age and asthma, then added BEC and LM ethmoid score. Performance was evaluated at 36 months and internally validated using 1000 bootstrap resamples. Results: Among 157 patients, 51 (32.5%) experienced recurrence; 36-month recurrence-free survival was 72.5% (95% confidence interval [CI], 64.7%-78.9%). Earlier recurrence was associated with age (adjusted hazard ratio [HR] per 10 years, 1.26; 95% CI, 1.03-1.53), asthma (HR, 2.00; 95% CI, 1.03-3.90), BEC (HR per 0.1 × 10 Conclusion: BEC and LM ethmoid score provided complementary information beyond age and asthma. External validation and recalibration are required before clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.